Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
You may also like
New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]
New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of precision […]
NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics […]
New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]